help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chopra, I. J.
Right arrow Articles by Younai, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chopra, I. J.
Right arrow Articles by Younai, S.

Journal of Clinical Endocrinology & Metabolism, Vol 80, 2178-2180, Copyright © 1995 by Endocrine Society

ARTICLES

Use of sodium ipodate in management of hyperthyroidism in subacute thyroiditis

IJ Chopra, AJ van Herle, SG Korenman, S Viosca and S Younai
Department of Medicine, University of California Center for the Health Sciences, Los Angeles 90024, USA.

Five hyperthyroid patients (two men and three women) with typical features of subacute thyroiditis were treated with sodium ipodate (Oragrafin; 0.5 g, orally daily or every other day) for 15-60 days; the treatment was stopped when both serum T4 and T3 levels were normal. All patients studied demonstrated a prompt normalization of serum T3, improvement in clinical symptoms of hyperthyroidism, and/or weight gain. We observed no side-effects of treatment with sodium ipodate. Our data suggest that sodium ipodate is a safe and effective agent for management of hyperthyroidism in subacute thyroiditis.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
P. Laurberg, H. Vestergaard, S. Nielsen, S. E. Christensen, T. Seefeldt, K. Helleberg, and K. M. Pedersen
Sources of Circulating 3,5,3'-Triiodothyronine in Hyperthyroidism Estimated after Blocking of Type 1 and Type 2 Iodothyronine Deiodinases
J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2149 - 2156.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. S. Dhillon, P. Cohan, D. F. Kelly, C. H. Darwin, K. V. Iyer, and I. J. Chopra
Treatment of Hyperthyroidism Associated with Thyrotropin-Secreting Pituitary Adenomas with Iopanoic Acid
J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 708 - 711.
[Abstract] [Full Text] [PDF]

Home page
 Canadian J. AnesthesiaHome page
C. K. Pandey, M. Raza, S. Dhiraaj, A. Agarwal, and P. K. Singh
Rapid preparation of severe uncontrolled thyrotoxicosis due to Graves' disease with Iopanoic acid - a case report: [La preparation rapide, avec de l'acide iopanoique, pour une thyrotoxicose severe non controlee causee par une maladie de Graves - une etude de cas]
Can J Anesth, January 1, 2004; 51(1): 38 - 40.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
I. J. Chopra and K. Baber
Use of Oral Cholecystographic Agents in the Treatment of Amiodarone-Induced Hyperthyroidism
J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4707 - 4710.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Braga and D. S. Cooper
Oral Cholecystographic Agents and the Thyroid
J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 1853 - 1860.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1995 by The Endocrine Society